Across TCGA pan-cancer cohorts, PBX2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PBX2 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PBX2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PBX2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.
HNSC, KIRC, and CESC are the cancer types where PBX2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.